Otricath

Houston, United States Founded: 2016 • Age: 10 yrs
A closed-loop catheter system is developed for liver cancer treatment.

About Otricath

Otricath is a Healthcare company based in Houston (United States) founded in 2016. A closed-loop catheter system is developed for liver cancer treatment. Otricath offers products and services including Otricath Platform and Therapy Delivery Device. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is NHC, LLC. Its competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Otricath was founded in 2016 in Houston, United States, within the medical device sector focused on oncology. A closed-loop catheter system is being developed to deliver treatment agents directly to liver tumor sites and extract them post-treatment. This approach is intended to limit agent migration to other body areas, thereby reducing side effects compared to conventional delivery methods. Operations center on advancing this technology for safer cancer interventions.

  • Headquarters Houston, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website otricath.com
  • Social X
  • Legal Name Nhc, Llc
Operational Areas

Products & Services of Otricath

Otricath offers a comprehensive portfolio of products and services, including Otricath Platform and Therapy Delivery Device.

Otricath Platform
Medical Device

Delivers cancer-fighting agents to solid tumors with control and safety.

Therapy Delivery Device
Oncology Technology

Provides predictable and safe agent delivery for cancer treatment.

Competitors of Otricath

Otricath has 3 listed competitors in our database, 3 of them funded. They include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
trisaluslifesci.com2009Westminster, United States$83.37M100
Developer of drug delivery devices to treat cancers
coolerheads.com1998San Diego, United States$23.11M
Developer of cold cap system to prevent chemotherapy side effects
cognosthx.com2015Los Angeles, United States$5.75M13
Cognos Therapeutics is focused on innovative neurological and oncological treatments.
Premium access

Detailed competitors of Otricath

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Otricath (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Otricath

Otricath was founded in 2016.

Otricath is headquartered in Houston, United States. It is registered at Houston, Texas, United States.

Otricath was founded in 2016 in Houston, United States, within the medical device sector focused on oncology. A closed-loop catheter system is being developed to deliver treatment agents directly to liver tumor sites and extract them post-treatment. This approach is intended to limit agent migration to other body areas, thereby reducing side effects compared to conventional delivery methods. Operations center on advancing this technology for safer cancer interventions.

Otricath's top competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.

Otricath offers Otricath Platform and Therapy Delivery Device.

Otricath operates through Nhc, Llc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available